A study of 830,393 adults found beta-3 agonists such as mirabegron were not associated with lower dementia risk than anticholinergic bladder drugs, including oxybutynin.
Newer Overactive Bladder Drugs Were Not Linked to Lower Dementia Risk Than Oxybutynin
by | Nov 7, 2026 | Uncategorized | 0 comments
Recent Comments